Protalix BioTherapeutics (PLX) EBT Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.17% |
| Dec 31, 2025 | -68.99% |
| Sep 30, 2025 | 20.03% |
| Jun 30, 2025 | 16.63% |
| Mar 31, 2025 | -35.39% |
| Dec 31, 2024 | 154.55% |
| Sep 30, 2024 | 25.14% |
| Jun 30, 2024 | 21.75% |
| Mar 31, 2024 | 8.68% |
| Dec 31, 2023 | -31.86% |
| Sep 30, 2023 | 20.90% |
| Jun 30, 2023 | 33.88% |
| Mar 31, 2023 | 16.81% |
| Dec 31, 2022 | 21.10% |
| Sep 30, 2022 | 20.80% |
| Jun 30, 2022 | 17.37% |
| Mar 31, 2022 | 23.01% |
| Dec 31, 2021 | 8.29% |
| Sep 30, 2021 | 10.69% |
| Jun 30, 2021 | -0.97% |
| Mar 31, 2021 | 7.74% |
| Dec 31, 2020 | 15.29% |
| Sep 30, 2020 | 5.46% |
| Jun 30, 2020 | 7.62% |
| Mar 31, 2020 | 17.33% |
| Mar 31, 2019 | -0.19% |
| Dec 31, 2018 | 20.20% |
| Sep 30, 2018 | 0.33% |
| Jun 30, 2018 | -4.37% |
| Mar 31, 2018 | -10.65% |
| Dec 31, 2017 | -0.64% |
| Sep 30, 2017 | -15.53% |
| Jun 30, 2017 | -28.03% |
| Mar 31, 2017 | -6.86% |
| Dec 31, 2016 | -2.86% |
| Sep 30, 2016 | 2.92% |
| Jun 30, 2016 | 4.82% |
| Mar 31, 2016 | -11.72% |
| Dec 31, 2015 | 0.50% |
| Sep 30, 2015 | -16.19% |
| Jun 30, 2015 | 9.31% |